Skip to main content
. 2020 Mar 12;21(6):1952. doi: 10.3390/ijms21061952

Figure 5.

Figure 5

Cellular uptake, mRNA and protein kinetics of lead candidate X07091 = NVP-13. (A and B) Cellular uptake kinetics of A549 (A) and ReNcell CX® (B) cells after 0–72 h of incubation with 10 µM X07091 = NVP-13 as measured with a specific bioprobe (n = 3). (C and D) TGFBR2 mRNA kinetics in A549 (C) and ReNcell CX® (D) established in a qRT-PCR over 6 d after a single treatment with 10 µM X07091 = NVP-13 (n = 3). TGFBR2 mRNA levels were normalized to the housekeeper Gnb2l and normalized to untreated cells. (E and F) Densitometric analysis of TGFBR2 protein levels (Western blot) in A549 (E) and ReNcell CX® (F) after 1, 4, 8, and 12 d of treatment with 10 µM X07091 = NVP-13 (n = 4 for A549 and n = 7 for ReNcell CX®). (G and H) Western Blot (WB) against TGFBR2 (Biorybt) in A549 (G) and ReNcell CX® (H). For qRT-PCR and WB, all values were normalized to untreated controls. Statistics was calculated by Ordinary-one-way-Anova followed by Dunnett’s multiple comparison test. * p ≤ 0.05, ** p ≤ 0.01, ± = SEM.